加载中
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
前收盘价
US$1.25
+US$0.02 · +1.63%
盘中时间采用ET。市场数据可能有所延迟。
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
日内区间
当前US$1.25
52周区间
当前US$1.25
盘中时间采用ET。市场数据可能有所延迟。
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
日内区间
当前US$1.25
52周区间
当前US$1.25
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 42.4万 USD | — | 35.7万 USD | — | — |
| 毛利 | −42.4万 USD | — | −35.7万 USD | — | — |
| 研究与开发 | 1812.6万 USD | 1574.5万 USD | 1696.8万 USD | 1416.9万 USD | 1100.2万 USD |
| 销售、一般及管理费用 | 943万 USD | 893.2万 USD | 999.7万 USD | 537.2万 USD | 232.1万 USD |
| 营业费用 | 2713.2万 USD | 2467.7万 USD | 2660.8万 USD | 2124.1万 USD | 1332.3万 USD |
| 折旧和摊销 | 42.4万 USD | 40万 USD | 35.7万 USD | 38.1万 USD | 34.5万 USD |
| 营业利润 | −2755.6万 USD | −2467.7万 USD | −2696.5万 USD | −2124.1万 USD | −1332.3万 USD |
| 净利润 | −2660.9万 USD | −2348.6万 USD | −2565.2万 USD | −1388.9万 USD | −1277.3万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.00
上涨空间 220.00%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年8月19日 | 1:3 | — | — |
股票拆分 | 2020年1月6日 | 1:8 | — | — |
已生效 2022年8月19日
1:3
已生效 2020年1月6日
1:8
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
